The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal ...

New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

A phase 1/2 trial reveals sacituzumab tirumotecan shows manageable toxicity and promising antitumor activity in patients with advanced solid tumors.

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

Enzalutamide's efficacy is supported by preference studies and a MAIC, helping doctors and patients make informed treatment ...